WAVE Life Sciences Ltd (WVE) Stock AnalysisWVEWAVE Life Sciences Ltd

Wave Life Sciences, Inc. is a clinical-stage biotechnology company focused on ribonucleic acid (RNA) medicines (also known as oligonucleotides), or those targeting RNA, to transform human health. The Company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNA interference (RNAi) (SpiNA) and RNA editing (AIMers), provides unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company's pipeline is focused on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs and also includes clinical programs for Duchenne muscular dystrophy (DMD) and Huntington's disease, as well as several preclinical programs utilizing its versatile RNA medicines platform. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

WAVE Life Sciences Ltd is not a good buy right now due to a current price of $3.13 and a very low RSI of 23.147, indicating oversold conditions. The company has reported a staggering net loss of $69.4 million in Q2 2026, which is a significant risk factor. Additionally, the stock has seen a year-to-date change of -80.38%, suggesting a severe decline in value.

6 analysts cover WVE: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 33.00.